Patents
Sitemap › C12 - Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or genetic engineering › C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media
More topics under "C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media" (918,689)
C12N 1 - Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor (148,866)
C12N 11 - Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof (12,439)
C12N 13 - Treatment of micro-organisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves (3,958)
C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
C12N 3 - Spore-forming or isolating processes (415)
C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor (182,629)
C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637)
C12N 9 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes (141,535)
Patents for C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media (9,992)
02/2005
02/24/2005US20050042634 B. anthracis prevention and treatment: mutant B. anthracis lacking luxS activity and furanone inhibition of growth, AI-2 quorum sensing, and toxin production
02/24/2005US20050042603 Protein fusion comprising nuclear localization signal domain for use as tool to enhance gene transfer into cells: gene therapy and heterologous gene expression
02/24/2005US20050042595 Banking of multipotent amniotic fetal stem cells
02/24/2005US20050042231 Useful in vaccines, and monoclonal antibodies against said immunogenic surface proteins; hybridoma cell line that produes said antibodies; use in diagnostic kits for determining presence, onset, or decrease in Leptospiral infection
02/24/2005US20050042207 Escherichia bacteria; diarrhea, autoimmune diseases, microbial infections, irritable bowel syndrome, and inflammatory bowel disease; side effect reduction
02/24/2005CA2852159A1 Metabolically engineered bacterial strains having non-functional endogenous gluconate transporters
02/24/2005CA2536146A1 Splice variants of erbb ligands, compositions and uses thereof
02/24/2005CA2535892A1 A stable liquid probiotic composition, preparation and applications thereof
02/24/2005CA2535863A1 Polypeptides of streptococcus pyogenes
02/24/2005CA2534629A1 Engineered proteases for affinity purification and processing of fusion proteins
02/24/2005CA2532027A1 Specific binding agents to hepatocyte growth factor
02/24/2005CA2526595A1 Metabolically engineered bacterial strains having non-functional endogenous gluconate transporters
02/24/2005CA2526120A1 Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
02/23/2005EP1507854A1 New improved acyltransferase
02/17/2005WO2005014798A2 Novel compositions and methods for promoting, inhibiting, and detecting protein entry into cells
02/17/2005WO2005014797A2 P16 mediated regulation of nmda receptors
02/17/2005WO2005014796A2 Methods and compositions for seamless cloning of nucleic acid molecules
02/17/2005WO2005014795A2 Osteoarthritis biomarkers and uses thereof
02/17/2005WO2005014794A2 Generation of low phytate plants by molecular disruption of inositol polyphosphate kinases
02/17/2005WO2005014793A2 Primary rat hepatocyte toxicity modeling
02/17/2005WO2005014792A2 Preservation of biomaterials with transported preservation agents
02/17/2005WO2005014791A2 Methods and compositions for targeted cleavage and recombination
02/17/2005WO2005014790A2 Polypeptides having oxaloecetate hydrolase activity and polynucleotides encoding same
02/17/2005WO2005014788A2 Tssk4: a human testis specific serine/threonine kinase
02/17/2005WO2005014787A2 Genetic elements conferring flower petal-specific transgene expression
02/17/2005WO2005014786A2 Enhanced engineered chromosome formation from alpha satellite with artificially increased density of cenp-b boxes
02/17/2005WO2005014785A2 Conditionally-immortalized hematopoietic progenitor cell lines
02/17/2005WO2005014784A2 System for molecular imaging
02/17/2005WO2005014781A2 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
02/17/2005WO2005014780A2 Prostate stem cell antigen (psca) variants and subsequences thereof
02/17/2005WO2005014779A2 Cyclodextrin affinity purification
02/17/2005WO2005014778A2 Dna vaccine expressing ha1 of equine-2 influenza virus
02/17/2005WO2005014777A2 Methods and compositions for increasing the efficacy of biologically-active ingredients
02/17/2005WO2005014775A2 Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a
02/17/2005WO2004108892A3 1,1-DISUBSTITUTEDCYCLOALKYL-, GLYCINAMIDYL-, SULFONYL-AMIDINO-, AND TETRAHYDROPYRIMIDINYL-CONTAINING DIAMINOALKYL, β-AMINOACIDS, α-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
02/17/2005WO2004108884A3 Composite materials and particles
02/17/2005WO2004108883A3 Transducible dna-binding proteins
02/17/2005WO2004096982A3 Antibacterial agents
02/17/2005WO2004092329A3 Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
02/17/2005WO2004083398A3 Therapeutic uses of hmgn1 and hmgn2
02/17/2005WO2004083397A3 Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
02/17/2005WO2004081189A9 Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and organisms
02/17/2005WO2004069991A3 Oligomeric compounds for the modulation of survivin expression
02/17/2005WO2004046310A3 Novel mouse polypeptides encoded by polynucleotides and methods of their use
02/17/2005US20050039220 Labeled coronavirus protein for use as diagnostic tool in detection of viral infection; viricides and vaccine development for treatment and prevention of respiratory system disorders
02/17/2005US20050037988 Determination competitive binder between Rna and target compound in plants
02/17/2005US20050037964 Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
02/17/2005US20050037471 Microfluidic rotary flow reactor matrix
02/17/2005US20050037459 Variant humicola grisea CBH1.1
02/17/2005US20050037455 Expression vector comprising antisense nuclelotide sequence which decrease exxpression from kinase suppressor of RAS (KRAS) for use in the treatment and prevention of cell proliferative disorders
02/17/2005US20050037433 Using N-methyl-D-aspartate (NMDA) receptor to identify modulators for treatment and prevention of neurodegenerative diseases
02/17/2005US20050037411 Thermostable peroxide-driven cytochrome P450 oxygenase variants and methods of use
02/17/2005US20050037409 Identifying and quantifying fusion protein comprising translocating markers that are responsive to altered cellular conditions; detecting vector transformed cell
02/17/2005US20050037394 preparing transcription reaction mixture comprising mutated polymerase, modified nucleotide triphosphates (NTPs), magnesium ions and oligonucleotide templates, partitioning high affinity nucleic acids, then replicating; point mutations; increased stability and half life
02/17/2005US20050037389 Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
02/17/2005US20050037387 Modulation of the RNA interference pathway
02/17/2005US20050036989 Subgroup B adenoviral vectors for treating disease
02/17/2005US20050036736 Etalon based compact dispersion module
02/17/2005CA2534909A1 P16 mediated regulation of nmda receptors
02/17/2005CA2534661A1 Osteoarthritis biomarkers and uses thereof
02/17/2005CA2534296A1 Methods and compositions for targeted cleavage and recombination
02/17/2005CA2533922A1 Primary rat hepatocyte toxicity modeling
02/17/2005CA2528606A1 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
02/17/2005CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof
02/17/2005CA2524767A1 Cyclodextrin affinity purification
02/17/2005CA2523676A1 Dna vaccine expressing ha1 of equine-2 influenza virus
02/17/2005CA2502148A1 Methods and compositions for increasing the efficacy of biologically-active ingredients
02/16/2005EP1506395A2 Liver inflammation predictive genes
02/16/2005EP1506302A2 Non-revertible beta-oxidation blocked candida tropicalis
02/16/2005CN1582331A Endothelial cells derived from primate embryonic stem cells
02/16/2005CN1189564C Modulators of the function of receptors of the TNF/NGF receptor family
02/15/2005US6855501 Transfer of arrayed chemical compositions
02/10/2005WO2005012502A2 Methods of identifying optimal variants of peptide epitopes
02/10/2005WO2005012501A2 Free-solution dna sequencing
02/10/2005WO2005012500A2 Arrays, methods and kits for preparation and use of syntenic genomic arrays for diagnostics and toxicology
02/10/2005WO2005012499A2 Methods for amplifying polymeric nucleic acids
02/10/2005WO2005012498A2 Production of porphyrins
02/10/2005WO2005012497A2 Translocation tagging
02/10/2005WO2005012496A2 Novel nucleic acids from sesame plants
02/10/2005WO2005012495A2 Methods for expression and purification of immunotoxins
02/10/2005WO2005012494A2 Treatment of organ transplant rejection
02/10/2005WO2005012493A2 Anti-cd19 antibodies
02/10/2005WO2005012492A2 Human skin equivalents expressing exogenous polypeptides
02/10/2005WO2005012491A2 Surface expression of biologically active proteins in bacteria
02/10/2005WO2005012490A2 Neuroprotective effects of atf6
02/10/2005WO2005012489A2 Targeting endothelium for tissue-specific delivery of agents
02/10/2005WO2005012487A2 Compositions and methods for preparing short rna molecules and other nucleic acids
02/10/2005WO2005012486A2 Metabolically engineered bacterial strains having enhanced 2-keto-d-gluconate accumulation
02/10/2005WO2005012485A2 Methods for treating diabetes and related disorders using pde10a inhibitors
02/10/2005WO2005012484A2 Antibody-toxin conjugates
02/10/2005WO2005012483A2 Vpr selective rnai agents and methods for using the same
02/10/2005WO2005012482A2 Assay for identification of bioactive compounds that interact with heat shock protein 90
02/10/2005WO2005012480A2 Systems and methods for separating and concentrating regenerative cells from tissue
02/10/2005WO2005012479A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
02/10/2005WO2004106489A3 Nematode GS-like sequences
02/10/2005WO2004101749A3 Methods for amplification of nucleic acid sequences using staggered ligation
02/10/2005WO2004081179A3 Regulation of rna stability
02/10/2005WO2004078916A3 In vitro micro-organs, and uses related thereto
02/10/2005WO2004065559A3 Power conditioners and pseudo isolation for a two-wire processing network
02/10/2005WO2004039953A3 Array oligomer synthesis and use.
1 ... 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 ... 100